News
-
-
PRESS RELEASE
Jaguar Health Satisfies Conditions for Receipt of Non-Dilutive $2 Million Holdback Payment from Future Pak for Commercial License to Mytesi and Canalevia-CA1
Jaguar Health receives $16M upfront payment in U.S. license agreement with Future Pak for crofelemer drugs. Presentation at ESPGHAN 2026 reveals positive results of crofelemer therapy for pediatric IF -
-
-
-
PRESS RELEASE
Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF) Due to Microvillus Inclusion Disease (MVID)
Jaguar announces compassionate use of crofelemer in EU for infant with IF due to MVID. Ongoing trials show promising results in reducing PS in pediatric patients for over a year -
-
PRESS RELEASE
Original-Research: Jaguar Health Inc (von First Berlin Equity Research GmbH): Under Review
First Berlin Equity Research updates rating and price target for Jaguar Health Inc (ISIN: US47010C8055) to 'Under Review' due to recent restructuring steps and ongoing liquidity concerns, while recognizing positive clinical developments -
-
PRESS RELEASE
Presentation at ESPGHAN 2026 Describes Additional Groundbreaking Results of Evaluation of Jaguar Health's Crofelemer as Adjunctive Oral Therapy for the Treatment of Pediatric Intestinal Failure (IF)
Jaguar Health, Inc. provides promising results on crofelemer for pediatric intestinal failure patients at ESPGHAN Meeting. Liquid oral crofelemer shows significant reductions in parenteral support requirements normalized to body weight
